Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIJIMEA K53
- Development stage
- Unknown
- Lead developer
- SYNformulas
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SYN-53 is a multi-strain probiotic food supplement developed by Synformulas GmbH, marketed under the brand name KIJIMEA K53. It contains a diverse blend of 53 selected bacterial strains designed to modulate the gut microbiome and address the immunological link between gut dysbiosis and allergic diseases. The product is specifically indicated for the management of allergic rhinoconjunctivitis (ARC), particularly symptoms triggered by grass pollen. In double-blind, placebo-controlled clinical trials using an allergen exposure chamber (AEC) model, SYN-53 demonstrated significant efficacy in reducing allergy symptom scores compared to placebo. Its therapeutic effect is attributed to the high diversity and concentration of its constituent microculture strains.
- Brand names
- KIJIMEA K53
02
Targets
Intestinal gut microbiome
Beyond the preview
Go deeper on KIJIMEA K53.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIJIMEA K53.